Munveer Singh Bhangoo1, Diraj R Karnani1, Paul N Hein1, Huan Giap1, Harry Knowles1, Chris Issa1, Steve Steuterman1, Paul Pockros1, Catherine Frenette1. 1. 1 Department of Internal Medicine, Scripps Green Hospital, La Jolla, CA, USA ; 2 New York University, School of Medicine, New York, NY, USA ; 3 Scripps Proton Center, San Diego, CA, USA ; 4 Department of Radiology, Scripps Green Hospital, La Jolla, CA, USA ; 5 Radiation Safety, Scripps Clinic, La Jolla, CA, USA ; 6 Center for Organ Transplantation, Scripps Green Hospital, La Jolla, CA, USA.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is aggressive primary malignancy of the liver that most commonly presents late in the disease course. As a result, the majority of patients are not candidates for curative therapies. Locoregional therapies including Yttrium-90 (Y-90) radioembolization play an important role in management of the vast majority of patients with HCC. METHODS: Patients with unnresectable HCC (n=17) treated with Y-90 radioembolization from 2005 to 2014 were evaluated retrospectively. Data was abstracted from medical records including patient charts, laboratory data, and imaging. Toxicities were recorded using Common Terminology Criteria 3.0. Response was recorded according to modified RECIST (mRECIST) criteria. RESULTS: Seventeen patients received 33 treatments with Y-90 radioembolization. A majority (65%) received TheraSphere with a minority (35%) receiving SIR-Spheres. The median treatment activity delivered was 1.725 gBq (range, 1.4-2.5 gBq). The median treatment dose delivered was 100 Gy (range, 90-120 Gy). The median lung shunt fraction was 2.02% (range, 1.5-4.1%). The most common clinical toxicity among all patients was nausea and vomiting (59%), primarily grade 1 and 2. Other post-treatment findings included abdominal pain (29%), fatigue (53%), and weight loss (18%). One patient developed a grade 5 gastric ulcer after the treatment. A clinical benefit, defined as patients achieving complete response (CR), partial response (PR) or stable disease (SD), was seen in 48% of patients. PR was seen in 24% of cases; progressive disease (PD) was noted in 35%. Patients survived for a median of 8.4 months (range, 1.3 to 21.1 months) after the first radioembolization treatment. Median survival after Y-90 treatment was 8.4 months among patients treated TheraSphere as compared with 7.8 months in patients treated with SIR-Spheres. The mean overall survival from the time of diagnosis was 11.7 months (range, 3.4 to 43.2 months). CONCLUSIONS: For patients with unresectable HCC, Y-90 radioembolization is a safe and well-tolerated procedure. Our experience suggests that a significant percentage of patients achieve clinical benefit including many with PR. Survival after treatment from this single-center, transplant center is in line with prior reports. Prospective, randomized data is required to compare radioembolization with other therapies including chemoembolization and systemic therapy with sorafenib.
BACKGROUND:Hepatocellular carcinoma (HCC) is aggressive primary malignancy of the liver that most commonly presents late in the disease course. As a result, the majority of patients are not candidates for curative therapies. Locoregional therapies including Yttrium-90 (Y-90) radioembolization play an important role in management of the vast majority of patients with HCC. METHODS:Patients with unnresectable HCC (n=17) treated with Y-90 radioembolization from 2005 to 2014 were evaluated retrospectively. Data was abstracted from medical records including patient charts, laboratory data, and imaging. Toxicities were recorded using Common Terminology Criteria 3.0. Response was recorded according to modified RECIST (mRECIST) criteria. RESULTS: Seventeen patients received 33 treatments with Y-90 radioembolization. A majority (65%) received TheraSphere with a minority (35%) receiving SIR-Spheres. The median treatment activity delivered was 1.725 gBq (range, 1.4-2.5 gBq). The median treatment dose delivered was 100 Gy (range, 90-120 Gy). The median lung shunt fraction was 2.02% (range, 1.5-4.1%). The most common clinical toxicity among all patients was nausea and vomiting (59%), primarily grade 1 and 2. Other post-treatment findings included abdominal pain (29%), fatigue (53%), and weight loss (18%). One patient developed a grade 5 gastric ulcer after the treatment. A clinical benefit, defined as patients achieving complete response (CR), partial response (PR) or stable disease (SD), was seen in 48% of patients. PR was seen in 24% of cases; progressive disease (PD) was noted in 35%. Patients survived for a median of 8.4 months (range, 1.3 to 21.1 months) after the first radioembolization treatment. Median survival after Y-90 treatment was 8.4 months among patients treated TheraSphere as compared with 7.8 months in patients treated with SIR-Spheres. The mean overall survival from the time of diagnosis was 11.7 months (range, 3.4 to 43.2 months). CONCLUSIONS: For patients with unresectable HCC, Y-90 radioembolization is a safe and well-tolerated procedure. Our experience suggests that a significant percentage of patients achieve clinical benefit including many with PR. Survival after treatment from this single-center, transplant center is in line with prior reports. Prospective, randomized data is required to compare radioembolization with other therapies including chemoembolization and systemic therapy with sorafenib.
Authors: Kent Sato; Robert J Lewandowski; James T Bui; Reed Omary; Russell D Hunter; Laura Kulik; Mary Mulcahy; David Liu; Howard Chrisman; Scott Resnick; Albert A Nemcek; Robert Vogelzang; Riad Salem Journal: Cardiovasc Intervent Radiol Date: 2006 Jul-Aug Impact factor: 2.740
Authors: Ravi Murthy; Rodolfo Nunez; Janio Szklaruk; William Erwin; David C Madoff; Sanjay Gupta; Kamran Ahrar; Michael J Wallace; Alan Cohen; Douglas M Coldwell; Andrew S Kennedy; Marshall E Hicks Journal: Radiographics Date: 2005-10 Impact factor: 5.333
Authors: Ana L Keppke; Riad Salem; Denise Reddy; Jie Huang; Jianhua Jin; Andrew C Larson; Frank H Miller Journal: AJR Am J Roentgenol Date: 2007-03 Impact factor: 3.959
Authors: M A D Vente; M Wondergem; I van der Tweel; M A A J van den Bosch; B A Zonnenberg; M G E H Lam; A D van Het Schip; J F W Nijsen Journal: Eur Radiol Date: 2008-11-07 Impact factor: 5.315
Authors: Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Ryan D Hirsch; Chris Mills; Rohit Sawhney; Siddharth Sood; Virginia Bird; Gauri Mishra; Anouk Dev; William Kemp; John Lubel; Stuart K Roberts; Paul Gow; Amanda J Nicoll Journal: J Gastrointest Cancer Date: 2021-09
Authors: Mohammad Elsayed; Bernard Cheng; Minzhi Xing; Ila Sethi; David Brandon; David M Schuster; Zachary Bercu; James Galt; Bruce Barron; Nima Kokabi Journal: Cardiovasc Intervent Radiol Date: 2020-10-01 Impact factor: 2.740
Authors: Mohammad Elsayed; William Wagstaff; Keywan Behbahani; Alexander Villalobos; Zachary Bercu; Bill S Majdalany; Mehmet Akce; David M Schuster; Hui Mao; Nima Kokabi Journal: Cardiovasc Intervent Radiol Date: 2021-07-26 Impact factor: 2.740
Authors: Andrew Gabrielson; Akemi Miller; Filip Banovac; Alexander Kim; Aiwu Ruth He; Keith Unger Journal: Front Oncol Date: 2015-12-23 Impact factor: 6.244